research use only
Cat.No.S5842
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other Dopamine Receptor Inhibitors | MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Rotundine Domperidone Sulpiride Azaperone ONC206 SCH-23390 hydrochloride |
|
In vitro |
DMSO
: 90 mg/mL
(199.29 mM)
Ethanol : 90 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 451.60 | Formula | C26H37N5O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 81409-90-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | FCE-21336 | SMILES | CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
D2 receptor
0.7 nM
5-HT2
1.2 nM
5-HT2B
1.2 nM
D3 receptor
1.5 nM
D4 receptor
9 nM
|
|---|---|
| In vitro |
Cabergoline prevents the oxidative stress-induced cell death of cultured cortical neurons via a D2 receptor-mediated mechanism. This compound suppresses the activation of ERK signaling, which might have a role in the neuroprotection. It significantly represses extracellular glutamate accumulation triggered by oxidative stress, and increases the expression of glutamate transporters including EAAC1, which is known to be involved in the clearance of extracellular glutamate.
|
| In vivo |
Cabergoline has a long elimination half-life (63 to 109 h). An in vivo study of neuronal damage induced by intracerebroventricular (icv) injection of 6-OHDA, a neurotoxic compound that selectively damages dopaminergic neurons in male ICR mice, demonstrates that intraperitoneal (ip) administration of this compound for 7 days prevented nigrostriatal region dopaminergic neurons from cell death. It also protects SH-SY5Y neuroblastoma from cell death by oxygen-glucose deprivation even when this chemical is administered after the induction of cell death. This compound increases hippocampal brain-derived neurotrophic factor (BDNF, an important regulator in the synaptic plasticity) and exerts an antidepressant effect in rats.
|
References |
(data from https://clinicaltrials.gov, updated on 2025-09-23)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07045935 | RECRUITING | Prolactinoma |
University Hospital, Basel, Switzerland |
2025-09-16 | PHASE4 |
| NCT07034859 | ENROLLING_BY_INVITATION | Pituitary Adenoma; MRI; RCT |
National Taiwan University Hospital |
2024-05-20 | PHASE4 |
| NCT07603466 | ENROLLING_BY_INVITATION | Cushing Disease Due to Increased ACTH Secretion |
University of Basrah |
2026-05-11 | PHASE4 |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT07386080 | NOT_YET_RECRUITING | Scizophrenia |
Zealand University Hospital |
2026-05-01 | PHASE4 |
| NCT07072910 | RECRUITING | Migraine |
Aarhus University Hospital |
2025-11-12 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.